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This study intended to determine the impact of HDL-c and/or TGs levels on patients with average LDL-c concentration, focusing
on lipidic, oxidative, inflammatory, and angiogenic profiles. Patients with cardiovascular risk factors (𝑛 = 169) were divided into
4 subgroups, combining normal and low HDL-c with normal and high TGs patients. The following data was analyzed: BP, BMI,
waist circumference and serum glucose, Total-c, TGs, LDL-c, oxidized-LDL, total HDL-c and HDL subpopulations, paraoxonase-
1 (PON1) activity, hsCRP, uric acid, TNF-𝛼, adiponectin, VEGF, and iCAM1. The two populations with increased TGs levels,
regardless of the normal or low HDL-c, presented obesity and higher waist circumference, Total-c, LDL-c, Ox-LDL, and uric acid.
Adiponectin concentration was significantly lower and VEGF was higher in the population with cumulative low values of HDL-c
and high values of TGs, while HDL quality was reduced in the populations with impaired values of HDL-c and/or TGs, viewed
by reduced large and increased small HDL subfractions. In conclusion, in a population with cardiovascular risk factors, low HDL-
c and/or high TGs concentrations seem to be associated with a poor cardiometabolic profile, despite average LDL-c levels. This
condition, often called residual risk, is better evidenced by using both traditional and nontraditional CV biomarkers, including
large and small HDL subfractions, Ox-LDL, adiponectin, VEGF, and uric acid.
1. Introduction
Dyslipidemia is recognized as one of the major risk factors
for the development of cardiovascular disease (CVD),
which remains the leading cause of death across Europe [1].
The 3-hydroxy-3-methylglutaryl-coenzyme (HMG-CoA)
reductase inhibitors, also known as statins, are the first-line
lipid-lowering agents for CVDpatients and have transformed
the treatment of dyslipidaemia. Effective antidyslipidemic
treatment significantly reduces cardiovascular risk: a 10%
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reduction in total cholesterol is associated with a 25%
reduction in the incidence of coronary artery disease (CAD)
at five years, and reducing low density lipoprotein choles-
terol (LDL-c) by 40mg/dL (1mmol/L) with statin therapy
leads to a 20% reduction in risk for coronary events
[2, 3]; for every mmol/L reduction in LDL-c, the risk of
coronary heart disease (CHD) mortality decreases by 19%
and overall mortality decreases by 12% [2, 4]. However, a
significant number of patients on statin therapy have per-
sistent dyslipidaemia, as demonstrated by the dyslip-
idemia international study (DYSIS) which reported data
from several European countries, including from Portugal
[5–8].
Recently, several authors have been focusing the attention
on the concept of residual cardiovascular risk (RCVR) [9, 10].
According toHermans and Fruchart, RCVR could be defined
by the “residual risk of incident vascular events or progression
of established vascular damage persisting in patients treated
with current evidence-based recommended care, including
risk from established risk factors, such as dyslipidemia, high
blood pressure, hyperglycemia, inflammation and unhealthy
lifestyles, and risk related to emerging or newer risk factors”
[10]. It is apparent that a greater number of residual cardio-
vascular events occur than are prevented with statin therapy;
indeed, the RCVR remains elevated even in clinical trials in
which LDL-c levels have been aggressively reduced [11–13].
As a result, there has been an increased focus on elevated
triglycerides (TGs) and decreased high density lipoprotein
cholesterol (HDL-c) levels and their significant contributions
to RCVR even when LDL-c levels are well controlled [14, 15].
Low levels ofHDL-c have been largely recognized as a risk
factor for CHD and high levels as a protective factor, accord-
ing to epidemiology studies performed in subjects and/or
patients not optimally treated with statins [16–18]. Although
HDL-c has been traditionally associated to atheroprotection,
the concept of “HDL-c quality” as an important parameter
in reducing cardiovascular mortality is constantly gaining
ground and HDL particle functionality has been recognized
as a putative pharmacological target for HDL-based therapies
[19–22]. HDL quality refers to the composition and functions
of HDL particle subpopulations present in a single individual
and may define whether HDL is atheroprotective or even
proatherogenic [19, 20]. It has been suggested thatmonitoring
the type of HDL particles (carry distinct and specific proteins
or lipids and differentiated by their density and size: large,
intermediate, and small), rather than their total quantity, is a
more reasonable way of determining the CV risk, suggesting
that different subpopulations may have a different role in
reverse cholesterol transport (RCT) and CVD risk protection
[23, 24]. However, defining HDL quality remains vague and
further studies are needed to clarify the true differences
between the particles of HDL and to justify their different
functionalities. Nevertheless, variations in HDL subfraction
levels and functions have been observed in distinct CVD
populations, suggesting that large HDL particles are inversely
associated with atherosclerosis development while small
HDL subpopulations are positively connectedwithCVD[20–
27].
On the other hand, some data suggest that hypertriglyc-
eridemia, as the result of TG-rich lipoproteins overproduc-
tion and/or decreased catabolism, is a major factor associated
with lack of goals attainment [28]. Elevated TGs levels are
considered an independent risk factor for CVD even when
controlling for the other factors [29–31], and treatment of
elevated TGs in clinical trials has been shown to reduce CVD
events, cardiac deaths, and total mortality [31–33]. Patients
with elevated TGs are at particularly high risk of CVD,
particularly when coexisting with low HDL-c levels [34, 35].
Due to the importance that the levels of HDL-c and TGs
have been gaining, the ratio TGs/HDL-c may become a new
relevant marker for the determination of cardiovascular risk.
In adults, the simple TGs/HDL-c index was shown to identify
patients with dyslipidemia and insulin resistance [36, 37]; in
overweight adults, Barter et al. [38] recently showed that only
those subjectswith an increase inTGs and a decrease inHDL-
c presented hypertension, elevated levels of CRP, and insulin
resistance. Furthermore, these studies reinforce the idea that
classic risk factors explain only about 50–60% of CVD [39];
thus, there has been an increasing interest in identifying novel
biomarkers that might improve the global risk prediction of
CVD [40, 41].
This study aimed to evaluate the influence of low HDL-
c and/or elevate TGs levels on the cardiometabolic profile
of patients with cardiovascular risk factors but average LDL-
c contents, using both traditional and new nontraditional
(emergent) markers, including HDL subpopulations, oxi-
dized LDL (Ox-LDL), and inflammatory and angiogenesis
mediators.
2. Materials and Methods
2.1. Subjects and Ethical Consideration. One hundred and
sixty nine patients with cardiovascular risk factors were
enrolled in the study, divided in two major groups based on
the HDL-c levels: a group of patients with normal HDL-c
levels (including 119 subjects, 71 males, and 48 females) and
another one with low HDL-c concentrations (of 50 patients,
17 males and 33 females), using the cutoffs of 1.03mmol/L
for men and 1.29mmol/L for women. In addition, each group
was subdivided into two subgroups on the basis of their TGs
levels: a subgroup of patients with normal TGs levels and
another one with high TGs contents, using the cutoff of < and
≥ of 1.69mmol/L. Thus, four subgroups were analyzed: (A)
normal HDL-c and normal TGs (𝑛 = 83), (B) normal HDL-c
and high TGs (𝑛 = 36), (C) low HDL-c and normal TGs (𝑛 =
17), and (D) low HDL-c and high TGs (𝑛 = 33). The cutoffs
for HDL-c and TGs levels were chosen according to the
NCEP-ATP III guidelines. All groups were defined as having
cardiovascular risk factors in terms of previous diagnosis
and/or pharmacological treatment for hypertension and/or
for type 2 diabetes mellitus (T2DM) and/or for dyslipidemia.
T2DMwas diagnosed in theDiabetes andMetabolic Diseases
Unit from the Coimbra Hospital Centre (EPE), according to
the European Guidelines. Patients presenting previous diag-
nosis and/or treatment for hypertension and dyslipidemia
were recruited during the performance of routine labora-
tory analysis where they expressed taking antihypertensive
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therapy and/or lipid-lowering drugs after proper clinical
and laboratorial diagnosis, which were performed according
to the International Society of Hypertension/World Health
Organization and the Seventh Joint National Committee on
Hypertension and National Cholesterol Education Program-
Adult Treatment Panel III (NCEP-ATP III) for hypertension
and dyslipidemia, respectively. The patients from the groups
of normal HDL-c and low HDL-c levels were under the
following medication, respectively: (a) insulin and/or oral
antidiabetic drugs (OAD): 57.98% and 68.00%; (b) lipid-
lowering drugs: 65.55% (78 out of 119) in the normal
HDL-c group, distributed by statins (58 patients), fibrates
(15 patients), and a combination of both (5 patients) and
60.00% (30 out of 50) in the low HDL-c group, distributed
by statins (21 patients), fibrates (6 patients), a combination
of both (1 patient), ezetemibe (1 patient), and omega-3 (1
patient); (c) antihypertensive drugs: 68.07% and 76.00%.
Pregnant women were excluded. The study was performed
in agreement with the code of ethics of the World Medical
Association (Declaration of Helsinki) for human studies and
received authorization from the local ethics committee, as
well as from all the participants by signing a written informed
consent.
2.2. Data and Blood Collection. The following data was
obtained from each subject by trained personnel: weight and
height (without shoes and wearing light outdoor clothing)
were measured in order to calculate body mass index (BMI),
waist circumference (WC), and systolic and diastolic blood
pressure (SBP and DBP), the latter of which were assessed
in the sitting position after a 5min rest. Blood samples were
collected by venipuncture from the subjects after an overnight
fasting period, via both EDTA-containing tubes and tubes
without anticoagulant, in order to obtain plasma, buffy-
coat, and serum and processed within 2 hours of collection.
Aliquots were immediately stored at −80∘C until assayed.
2.3. Assays
2.3.1. Lipid and Glycemic Profiles. Serum total cholesterol
(Total-c), HDL-c, LDL-c, and TGswere analysed on aHitachi
717 analyser (Roche Diagnostics) using standard laboratorial
methods. Total-c reagents and TGs kit were obtained from
bioMe´rieux sa (Lyon, France). HDL-c Plus and LDL-c Plus
tests were obtained from F. Hoffmann-La Roche Ltd (Roche
Diagnostics Div., Basel, Switzerland). Plasma concentrations
of Ox-LDL were evaluated by using a standard commer-
cial enzyme-linked immunoassay (Oxidized LDL ELISA,
Mercodia, Uppsala, Sweden). Serum glucose levels were
measured using aGlucoseOxidase commercial kit (Sigma, St.
Louis, MO, USA). HbA1c levels were analyzed on a Hitachi
717 analyser (Roche Diagnostics) using standard laboratory
methods.
2.3.2. HDL Subpopulations Assay. Subpopulationswere sepa-
rated and quantified using a Lipoprint kit fromQuantimetrix
Corp. (Redondo Beach, CA, USA). The assay involves a
polyacrylamide gel electrophoresis assay and a complete
Lipoprint System for data acquisition and quantification of
large, intermediate, and small subpopulations of HDL.
2.3.3. PON1 Paraoxonase Activity. It was assessed spectro-
photometrically and expressed in nmol of p-nitrophenol/
mL/min. In brief, paraoxonase activity was measured by
adding serum to 1mL Tris/HCl buffer (100mmol/L, pH 8.0)
containing 2mmol/L CaCl
2
and 5.5mmol/L paraoxon (O,O-
diethyl-O-p-nitrophenylphosphate; Sigma Chemical Co).
The rate of generation of p-nitrophenol was determined at
412 nm, 37∘C, via the use of a continuously recording spectro-
photometer (Beckman DU-68).
2.4. Serum Inflammatory, Angiogenic, and Endothelial Mark-
ers. Serum adiponectin, tumor necrosis factor alpha (TNF-
𝛼), and vascular endothelial growth factor (VEGF) contents
were assessed using Quantikine enzyme-linked immunoas-
says kits from R&D Systems (Minneapolis, USA); serum
intercellular adhesion molecule 1 (iCAM1) levels were eval-
uated by using an Elisa kit from Abcam (Cambridge, MA,
USA); high-sensitivity C-reactive protein (hsCRP) was eval-
uated by immunoturbidimetry, using commercially available
kits (CRP [latex] High-Sensitivity, Roche Diagnostics); uric
acid was analyzed on a Hitachi 717 analyser (Roche Diagnos-
tics) using standard laboratory methods.
2.5. Statistical Analysis. Statistical analysis was performed by
using the IBM Statistical Package for Social Sciences (SPSS)
for Windows, version 20.0, (SPSS, Inc., Chicago, IL, USA).
The distribution of continuous variables was analyzed using
Kolmogorov-Smirnov tests, to assess significant departures
from normality. Comparisons between groups were per-
formed using the Independent Samples t-test and the Mann-
Whitney test. The association between categorical variables
was analyzed using Pearson’s test. Statistical significance was
accepted at 𝑃 less than 0.05.
3. Results
3.1. Anthropometric Data and General Characterization of
Populations. One hundred and sixty nine patients were en-
rolled in the study: 119 with normal HDL-c values and 50
with low HDL-c contents. From the normal HDL-c group,
the subgroupwith normal TGs levels (populationA) included
83 subjects and the subgroup with high TGs values (pop-
ulation B) included 36 individuals. Concerning the group
with low HDL-c contents, 17 subjects were included in the
subgroup with normal TGs contents (population C) and 33
individuals in the subgroup with high TGs levels (population
D). Throughout the text, three main comparisons will be
analyzed as a way to better dissect the differences and the
effects of HDL-c and TGs levels variations on the distinct cir-
cumstances (as indicated in the tables): comparison 1: effects
of TGs levels (normal versus high) on normal and low HDL-
c conditions/populations, by comparing population A with B
and C with D; comparison 2: effects of HDL-c levels (normal
versus low) on normal and high TGs conditions/populations,
by comparing populationAwith C and BwithD; comparison
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3: effects of variations of both HDL-c and TGs levels, by
comparing population A with D and B with C.
The demographic and anthropometric data of the 4
populations are summarized in Table 1. The normal and low
HDL-c groups are matched concerning age, without changes
between the 4 populations, while there were higher values of
BMI andwaist circumference in the subgroupswith high TGs
contents, independently of the HDL-c levels (populations B
and D). The same populations also demonstrated a trend
to higher glycemia contents, despite being not statistically
significant. Concerning blood pressure, unchanged values
were found between the subgroups in all the comparisons
(Table 1).
3.2. Classical Lipid Profile. The majority of the patients were
under antidyslipidemic therapy, which can justify some of the
data obtained for the classic lipid profile. Concerning the first
comparison (effects of TGs levels), the population B (with
high TGs contents and normal HDL-c levels) presented, in
comparison with the population A (with normal TGs and
normal HDL-c levels), significantly higher values of all the
lipidic parameters, including Total-c, TGs (as expected, by
definition of groups), LDL-c, Ox-LDL, non-HDL-c, Total-
c/HDL-c, LDL-c/HDL-c, and TGs/HDL-c (Table 2 and Fig-
ure 1(c)). Under conditions of low HDL-c, the subgroup
with high TGs (population D) also presented significantly
higher values of Total-c, TGs, non-HDL-c, Total-c/HDL-c,
and TGs/HDL-c.
Concerning the second comparison (effects of HDL-c
levels), independently of the TGs contents (normal or high)
the populations with low-HDL-c presented higher TGs,
Total-c/HDL-c, LDL-c/HDL-c, and TGs/HDL-c, without
changes on LDL-c, Ox-LDL, and non-HDL-c (Table 2 and
Figure 1(c)).
Finally, the effects of simultaneous variations of TGs and
HDL-c (comparison 3) were more pronounced when both
parameters are out of average values: comparing the popula-
tion A (of normal HDL-c and TGs) with the population D (of
lowHDL-c andhighTGs); in fact, the populationDpresented
significantly higher values of Total-c, TGs, LDL-c, Ox-LDL,
non-HDL-c, Total-c/HDL-c, LDL-c/HDL-c, and TGs/HDL-c
(Table 2 and Figure 1(c)). When comparing the population B
(of normal HDL-c and high TGs) with the population C (of
low HDL-c and normal TGs), the lipidic profile was clearly
worse when TGs are higher than when HDL-c is low; in
fact, population B presented significantly higher values of
Total-c, TGs, non-HDL-c, LDL-c/HDL-c, and TGs/HDL-c
(Table 2).
3.3. HDL Subpopulations and Paraoxonase Activity. Regard-
ing the content of HDL subpopulations, Table 2 and Figures
1(a) and 1(b) express the effects of HDL-c and TGs levels.
The lower values of HDL-c or the higher values of TGs
both promoted the poor quality of HDL, viewed by sig-
nificantly reduced percentage of large HDL subpopulations
and increased percentage of small HDL ones. Paraoxonase
activity was unchanged between the 4 populations under
study in all the comparisons (Table 2).
3.4. Markers of Inflammation, Angiogenesis, and Endothe-
lial Lesion. hsCRP, TNF-𝛼, and iCAM-1 contents were
unchanged between populations, despite a trend to reduce
iCAM-1 in the population D (of low HDL-c and high TGs
levels), which is significantly lower when compared with the
population A (of normal HDL-c and normal TGs levels)
(Table 3). Adiponectin concentration is significantly lower
only in the subgroup with low HDL-c and high TGs (popu-
lation D), and the value is statistically significant when com-
pared with the population A (of normal HDL-c and normal
TGs levels) andwith populationC (of lowHDL-c and normal
TGs levels) (Table 3 and Figure 2(a)). Similar profile was
encountered for VEGF, with a significantly higher content in
the subgroup with simultaneous change of HDL-c and TGs
(populationD), being statistically significant when compared
with the subgroup with normal levels of both HDL-c and
TGs (population A) (Table 3 and Figure 2(b)). Finally, uric
acid values were higher in the subgroups with high TGs
(population B versus A and D versus C), independently of
normal or low HDL-c levels (Table 3 and Figure 2(c)).
3.5. Analysis of Correlations between Markers of CV Risk in
All Study Subgroups. For some previously describedmarkers,
which presented changes between subgroups, there were
significant correlations, particularly in the population A.
The most interesting parameters in the correlation analysis
were the large and small HDL subpopulations, Ox-LDL,
adiponectin, uric acid, and waist circumference.
The values of Ox-LDL in the normal HDL-c and normal
TGs subgroup (population A) were negatively and signifi-
cantly correlated with large HDL (𝑟 = −0.295, 𝑃 = 0.014) and
positively and significantly correlated with small HDL (𝑟 =
0.430, 𝑃 = 0.000); these correlations were not found in the
3 other populations (Figure 3). Concerning adiponectin, in
the population A there was a significant positive correlation
with large HDL (𝑟 = 0.276, 𝑃 = 0.024) and a trend to
a negative correlation with small HDL (𝑟 = −0.162, 𝑃 =
0.192); these correlations were not found in the other 3
populations (Figure 4). Furthermore, also in the population
A, adiponectin was negatively and significantly correlated
with waist circumference (𝑟 = −0.363, 𝑃 = 0.004) and uric
acid (𝑟 = −0.361, 𝑃 = 0.016), which also correlates positively
and significantly waist circumference (𝑟 = 0.544, 𝑃 = 0.000);
once again, these correlations were absent (not statistically
significant) in the other 3 populations (Figure 5).
4. Discussion
It is now widely recognized that the current lipid-lowering
therapies, in particular those directed to reduce LDL-c levels,
such as statins, are insufficient to prevent part of the cardio-
vascular events; indeed, residual cardiovascular risk (RCVR)
remains elevated even in clinical trials in which LDL-c levels
have been aggressively reduced [11–13, 42–44]. As a result,
there has been an increased focus on elevated TGs levels
and low HDL-c levels and their significant contributions to
RCVR evenwhen LDL-c levels are well controlled [14, 15]. For
example, Genest et al. reported that although 34% of patients
The Scientific World Journal 5
Ta
bl
e
1:
A
nt
hr
op
om
et
ric
da
ta
an
d
ge
ne
ra
lc
ha
ra
ct
er
iz
at
io
n
of
th
ep
op
ul
at
io
ns
un
de
rs
tu
dy
.
Pa
ra
m
et
er
s
(1
)E
ffe
ct
so
fT
G
sl
ev
els
(n
or
m
al
ve
rs
us
hi
gh
)o
n
no
rm
al
an
d
lo
w
H
D
L-
cc
on
di
tio
ns
/p
op
ul
at
io
ns
(2
)E
ffe
ct
so
fH
D
L-
cl
ev
els
(n
or
m
al
ve
rs
us
hi
gh
)o
n
no
rm
al
an
d
hi
gh
TG
sc
on
di
tio
ns
(3
)E
ffe
ct
so
fv
ar
ia
tio
ns
of
bo
th
H
D
L-
ca
nd
TG
sl
ev
els
N
or
m
al
H
D
L-
c(
𝑛
=
1
1
9
)
Lo
w
H
D
L-
c(
𝑛
=
5
0
)
N
or
m
al
TG
s
(𝑛
=
8
3
)
Po
pu
la
tio
n
A
H
ig
h
TG
s
(𝑛
=
3
6
)
Po
pu
la
tio
n
B
𝑃
A
ve
rs
us
B
N
or
m
al
TG
s
(𝑛
=
1
7
)
Po
pu
la
tio
n
C
H
ig
h
TG
s
(𝑛
=
3
3
)
Po
pu
la
tio
n
D
𝑃
C
ve
rs
us
D
(N
or
m
al
TG
s)
𝑃
(A
ve
rs
us
C)
(H
ig
h
TG
s)
𝑃
(B
ve
rs
us
D
)
𝑃
A
ve
rs
us
D
𝑃
B
ve
rs
us
C
A
ge
(y
ea
rs
)
6
0
.1
2
±
1
.0
6
5
8
.6
9
±
1
.7
8
0.
49
1
6
1
.8
8
±
2
.7
6
6
0
.4
2
±
1
.3
6
0.
64
0
0.
50
8
0.
44
9
0.
87
3
0.
32
4
BM
I(
Kg
/m
2 )
2
8
.5
2
±
0
.5
2
3
0
.7
3
±
0
.7
7
0.
02
0
2
8
.2
7
±
0
.8
5
3
0
.6
9
±
0
.8
1
0.
04
6
0.
83
9
0.
97
2
0.
02
7
0.
04
8
W
C
(c
m
)
1
0
2
.1
6
±
1
.6
0
1
0
6
.6
1
±
1
.7
5
0.
04
9
9
7
.7
1
±
2
.7
8
1
0
5
.4
2
±
2
.7
4
0.
04
5
0.
22
8
0.
70
7
0.
30
6
0.
00
7
SB
P
(m
m
H
g)
1
4
0
.6
4
±
2
.6
8
1
3
9
.1
8
±
3
.1
0
0.
74
8
1
3
6
.1
2
±
5
.8
3
1
3
4
.3
3
±
3
.5
8
0.
78
5
0.
48
5
0.
25
9
0.
19
1
0.
93
9
D
BP
(m
m
H
g)
7
7
.8
5
±
1
.4
2
7
8
.4
0
±
2
.1
9
0.
83
0
7
4
.8
2
±
3
.6
2
7
5
.6
7
±
2
.2
7
0.
83
8
0.
39
2
0.
38
9
0.
41
4
0.
53
5
G
ly
ce
m
ia
(m
m
ol
/L
)
7
.8
8
±
0
.4
1
8
.9
2
±
0
.6
4
0.
09
6
7
.6
2
±
0
.8
0
9
.9
4
±
0
.7
6
0.
06
4
0.
75
9
0.
40
4
0.
01
5
0.
08
4
H
bA
1c
(%
)
7
.9
0
±
0
.2
4
8
.6
1
±
0
.4
7
0.
14
3
8
.4
2
±
0
.7
5
9
.7
5
±
0
.4
4
0.
12
6
0.
43
1
0.
08
2
0.
00
0
0.
83
3
Re
su
lts
ar
e
pr
es
en
te
d
as
m
ed
ia
±
SE
M
.I
nd
ep
en
de
nt
sa
m
pl
es
𝑡
-te
st
an
d
M
an
n-
W
hi
tn
ey
te
st
fo
rn
or
m
al
iz
ed
an
d
no
nn
or
m
al
iz
ed
sa
m
pl
es
,r
es
pe
ct
iv
ely
.B
M
I:
bo
dy
m
as
si
nd
ex
;H
bA
1c
:g
ly
ca
te
d
he
m
og
lo
bi
n;
SB
P:
sy
sto
lic
bl
oo
d
pr
es
su
re
;D
BP
:d
ia
sto
lic
bl
oo
d
pr
es
su
re
;W
C:
w
ai
st
ci
rc
um
fe
re
nc
e.
6 The Scientific World Journal
Ta
bl
e
2:
M
ar
ke
rs
of
lip
id
pr
ofi
le
of
th
ep
op
ul
at
io
ns
un
de
rs
tu
dy
.
Pa
ra
m
et
er
s
(1
)E
ffe
ct
so
fT
G
sl
ev
els
(n
or
m
al
ve
rs
us
hi
gh
)o
n
no
rm
al
an
d
lo
w
H
D
L-
cc
on
di
tio
ns
/p
op
ul
at
io
ns
(2
)E
ffe
ct
so
fH
D
L-
cl
ev
els
(n
or
m
al
ve
rs
us
hi
gh
)o
n
no
rm
al
an
d
hi
gh
TG
sc
on
di
tio
ns
(3
)E
ffe
ct
so
fv
ar
ia
tio
ns
of
bo
th
H
D
L-
ca
nd
TG
sl
ev
els
N
or
m
al
H
D
L-
c(
𝑛
=
1
1
9
)
Lo
w
H
D
L-
c(
𝑛
=
5
0
)
N
or
m
al
TG
s
(𝑛
=
8
3
)
Po
pu
la
tio
n
A
H
ig
h
TG
s
(𝑛
=
3
6
)
Po
pu
la
tio
n
B
𝑃
A
ve
rs
us
B
N
or
m
al
TG
s
(𝑛
=
1
7
)
Po
pu
la
tio
n
C
H
ig
h
TG
s
(𝑛
=
3
3
)
Po
pu
la
tio
n
D
𝑃
C
ve
rs
us
D
(N
or
m
al
TG
s)
𝑃
(A
ve
rs
us
C)
(H
ig
h
TG
s)
𝑃
(B
ve
rs
us
D
)
𝑃
A
ve
rs
us
D
𝑃
B
ve
rs
us
C
To
ta
l-c
(m
m
ol
/L
)
4
.6
0
±
0
.1
0
5
.5
4
±
0
.2
0
0.
00
0
4
.4
8
±
0
.1
9
5
.4
5
±
0
.2
0
0.
00
4
0.
59
9
0.
76
8
0.
00
0
0.
00
2
TG
s(
m
m
ol
/L
)
1
.0
6
±
0
.0
3
2
.5
3
±
0
.1
3
0.
00
0
1
.2
3
±
0
.0
7
3
.2
3
±
0
.1
9
0.
00
0
0.
04
9
0.
00
6
0.
00
0
0.
00
0
H
D
L-
c(
m
m
ol
/L
)
1
.5
0
±
0
.0
3
1
.4
2
±
0
.0
4
0.
22
9
1
.0
4
±
0
.0
4
1
.0
0
±
0
.0
3
0.
38
5
0.
00
0
0.
00
0
0.
00
0
0.
00
0
La
rg
eH
D
L
(%
)
3
7
.5
4
±
1
.2
5
2
9
.4
1
±
1
.8
3
0.
00
0
2
6
.1
0
±
2
.3
8
2
8
.1
6
±
2
.0
6
0.
54
1
0.
00
0
0.
64
6
0.
00
0
0.
29
5
In
te
rm
H
D
L
(%
)
4
4
.8
3
±
0
.7
2
4
5
.7
4
±
0
.9
7
0.
47
4
4
8
.9
5
±
1
.3
6
4
7
.4
2
±
1
.3
4
0.
66
7
0.
01
7
0.
31
1
0.
07
1
0.
06
4
Sm
al
lH
D
L
(%
)
1
7
.6
2
±
0
.7
2
2
4
.8
4
±
1
.5
7
0.
00
0
2
4
.9
2
±
2
.9
9
2
4
.3
2
±
2
.0
6
0.
93
7
0.
00
5
0.
99
1
0.
00
0
0.
92
7
LD
L-
c(
m
m
ol
/L
)
2
.6
1
±
0
.0
9
3
.0
2
±
0
.1
9
0.
04
9
2
.8
9
±
0
.1
8
3
.0
9
±
0
.2
0
0.
51
7
0.
17
6
0.
83
1
0.
02
9
0.
93
7
O
x-
LD
L
(U
/L
)
3
3
.6
5
±
1
.4
0
4
0
.0
0
±
2
.4
3
0.
01
8
3
8
.5
5
±
2
.7
7
4
0
.8
3
±
3
.0
1
0.
82
5
0.
14
8
0.
83
0
0.
01
6
0.
72
8
O
x-
LD
L/
LD
L-
c
1
2
.8
5
±
0
.3
9
1
3
.7
3
±
0
.6
8
0.
22
9
1
3
.3
4
±
1
.0
2
1
4
.3
3
±
0
.8
4
0.
47
6
0.
61
6
0.
57
2
0.
15
3
0.
65
5
N
on
-H
D
L-
c
(m
m
ol
/L
)
3
.1
0
±
0
.0
9
4
.1
2
±
0
.2
1
0.
00
0
3
.4
4
±
0
.1
8
4
.4
5
±
0
.1
9
0.
00
2
0.
11
1
0.
24
2
0.
00
0
0.
04
7
To
ta
l-c
/H
D
L-
c
3
.1
7
±
0
.0
8
4
.0
3
±
0
.1
9
0.
00
0
4
.4
0
±
0
.2
5
5
.5
6
±
0
.2
3
0.
00
2
0.
00
0
0.
00
0
0.
00
0
0.
19
4
LD
L-
c/
H
D
L-
c
1
.8
2
±
0
.0
8
2
.2
2
±
0
.1
6
0.
03
7
2
.8
4
±
0
.2
3
3
.1
5
±
0
.2
3
0.
53
9
0.
00
0
0.
00
1
0.
00
0
0.
03
2
TG
s/
H
D
L-
c
(m
m
ol
/L
)
0
.7
5
±
0
.0
3
1
.8
5
±
0
.1
2
0.
00
0
1
.2
0
±
0
.0
9
3
.3
8
±
0
.2
5
0.
00
0
0.
00
0
0.
00
0
0.
00
0
0.
00
0
PO
N
1a
ct
iv
ity
4
8
7
.2
3
±
1
6
.0
4
5
0
9
.1
2
±
3
7
.3
6
0.
59
3
5
2
3
.4
3
±
6
4
.7
9
5
0
3
.5
2
±
3
9
.3
6
0.
77
8
0.
77
6
0.
91
8
0.
90
2
0.
81
0
Re
su
lts
ar
ep
re
se
nt
ed
as
m
ed
ia
±
SE
M
.I
nd
ep
en
de
nt
sa
m
pl
es
𝑡
-te
st
an
d
M
an
n-
W
hi
tn
ey
te
st
fo
rn
or
m
al
iz
ed
an
d
no
nn
or
m
al
iz
ed
sa
m
pl
es
,r
es
pe
ct
iv
ely
.H
D
L-
c:
hi
gh
-d
en
sit
yl
ip
op
ro
te
in
ch
ol
es
te
ro
l;L
D
L-
c:
lo
w
-d
en
sit
y
lip
op
ro
te
in
ch
ol
es
te
ro
l;
O
x-
LD
L:
ox
id
iz
ed
lo
w
-d
en
sit
y
lip
op
ro
te
in
;T
G
s:
tr
ig
ly
ce
rid
es
;T
ot
al
-c
:t
ot
al
ch
ol
es
te
ro
l.
The Scientific World Journal 7
Large HDL
(%
)
20
30
40
∗∗∗
∗∗∗
∗∗∗
(a)
(%
)
10
20
30
Small HDL
∗∗∗
∗∗∗
∗∗
(b)
(U
/L
)
25
35
45
Ox-LDL
Normal HDL-c and normal TGs (population A)
Normal HDL-c and high TGs (population B)
Low HDL-c and normal TGs (population C)
Low HDL-c and high TGs (population D)
∗
∗
(c)
Figure 1: Serum Large HDL (a), small HDL (b), and Ox-LDL (c), in the study populations. Results are presented as mean ± SEM. ∗𝑃 <
0.05,∗∗𝑃 < 0.01, and ∗∗∗𝑃 < 0.001.
with premature heart disease had LDL-c levels > 160mg/dL,
more than half of the patients with premature heart disease
(57%) had low HDL-c levels [34, 45]. Additionally, it has
been reported that, in both male and female patients with
premature CAD, the greatest risk factor is actually lowHDL-c
levels, though these individuals often possess high TGs levels
as well. Conversely, the study found that TGs levels were
significantly higher andHDL-c levels were significantly lower
in men and women with premature CAD, compared with
patients from the FraminghamOffspring Studywhowere free
of CHD at baseline [14, 34].
Low levels of HDL-c and elevated levels of TGs have
been largely recognized as risk factors for coronary heart
and/or artery disease [16–18, 29–31], particularly in patients
with both conditions [34, 35]. Thus, in statin-medicated
patients, with average LDL-c levels, HDL-c and TGs have
been gaining particular relevance, as goodmeasures of RCVR
and target for prevention of cardiovascular events. Several
lines of evidence reinforce the idea that traditional risk
factors, including lipidic (such as LDL-c), might not tell the
whole story about CVD progression and prevention of CV
events, and thus, other lipid fractions/components, such as
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Figure 2: Serum adiponectin (a), VEGF (b), and uric acid (c) levels, in the study populations. Results are presented asmean±SEM. ∗𝑃 < 0.05,
∗∗
𝑃 < 0.01, and ∗∗∗𝑃 < 0.001.
HDL, TGs, and oxidized LDL (Ox-LDL), might have a major
role as biomarkers and/or targets to the reduction of overall
cardiovascular health [14, 15, 46, 47]. Actually, there has been
an increasing interest in identifying novel biomarkers, includ-
ing lipidic, inflammatory, and angiogenic, thatmight improve
the global risk prediction of CVD [40, 41]. The present study
aimed to evaluate the influence of low HDL-c and/or elevate
TGs levels and the relative relevance of each one alone and
combined on the cardiometabolic profile of patients with
cardiovascular risk factors but average LDL-c contents, using
both traditional and new nontraditional (emergent) markers,
including HDL subpopulations, Ox-LDL, and inflammatory
and angiogenesis mediators.
The main finding of this study is that patients with con-
trolled LDL-c levels, as a result of antidyslipidemic therapy,
in particular with statins, present a poor cardiometabolic
profile as a result of isolate or combined low-HDL-c dyslipi-
demia and hypertriglyceridemia. This cardiometabolic pro-
file, which might be viewed as a residual (but not negligible)
cardiovascular risk, is better diagnosed when analyzed in
terms of nontraditional markers, including large and small
HDL subpopulations, Ox-LDL, adiponectin, VEGF, and uric
acid.
Regarding the obesity profile, the results clearly show that
patients with elevated TGs levels, regardless of the HDL-c
values (normal or low concentrations), present the highest
10 The Scientific World Journal
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𝑃 = 0.115.
BMI (above 30 kg/m2) and waist circumference values. Sev-
eral studies have linked obesity to high TGs and low HDL-
c levels [48, 49]. In our study, elevated concentration of
TGs is more important in determining obesity in patients
with cardiovascular risk factors. This is better viewed when
comparing patients with average TGs contents and normal
HDL-c (population A) versus low HDL-c (population C)
levels, showing unchanged values between the groups, despite
both populations already presenting overweight (with BMI
above 28 kg/m2 for both). Similar profile was encountered for
Total-cwith significantly higher levels in the populationswith
elevated TGs contents, regardless of HDL-c concentration.
Concerning LDL-c and Ox-LDL, we found that the highest
values are encountered in the populations with high TGs
concentrations, despite a trend of increased contents in the
population with lowHDL-c values and normal TGs contents.
Thus, once again, elevated concentration of TGs is more
important than HDL-c in determining the values of LDL-c
and of Ox-LDL, in patients with cardiovascular risk factors
and under antidyslipidemic medication.
The association between cardiovascular disease and oxi-
dation of LDL has been largely demonstrated and previous
studies have reported an interesting relationship between
Ox-LDL and markers of lipid profile, in populations with
The Scientific World Journal 11
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cardiovascular risk as well as in healthy individuals [27,
50]. One of the most relevant associations is related with
inverse relationship and opposite roles of oxidized LDL and
HDL-c on atherogenesis and CAD [47, 51–53]. Concerning
the CAD, Ox-LDL is a promoter of key steps in the onset
and evolution of atherosclerosis, including stimulation of
monocyte infiltration and smooth muscle cell migration and
proliferation; conversely, high levels of HDL-c prevent the
development of atherosclerosis and CAD, in particular due
to the transport of reserve cholesterol and the inhibition
of Ox-LDL-induced monocyte infiltration; indeed, Ox-LDL
and HDL-c are antagonists in the development of CVD [51].
Our previous studies, both in healthy individuals and in
populations with cardiovascular risk, such type 2 diabetes
patients, strongly suggested an association between Ox-LDL
and HDL subpopulations, which was less evident with total
HDL-c content [25, 26]. In fact, Ox-LDL concentrations
showed an inverse and significant correlation with the large
HDL subfractions, those viewed as more atheroprotective,
and a direct and significant correlation with the small
HDL subpopulations, which are indicated as the atherogenic
ones, or at least less atheroprotective [25, 26]. Our present
study reinforces these associations, since Ox-LDL levels
presented the same significant correlation with the HDL
12 The Scientific World Journal
Ad
ip
on
ec
tin
 (𝜇
g/
m
L)
40
20
0
Ad
ip
on
ec
tin
 (𝜇
g/
m
L)
40
20
0
(A1)
Waist circumference (cm)
60 80 100 120 140
Waist circumference (cm)
(A2)
60 80 100 120 140
r = −0.363
P = 0.004
r = −0.006
P = 0.976
r = −0.012
P = 0.968
r = −0.093
P = 0.688
(a)
0
10
20
30
Ad
ip
on
ec
tin
 (𝜇
g/
m
L)
0
10
20
30
Ad
ip
on
ec
tin
 (𝜇
g/
m
L)
r = −0.361
P = 0.016
r = −0.310
P = 0.227
r = −0.354
P = 0.098
r = −0.493
P = 0.148
Uric acid (mmol/L)
0.0 0.5 1.0 1.5
(B1)
Uric acid (mmol/L)
0.0 0.5 1.0 1.5
(B2)
(b)
Waist circumference (cm) Waist circumference (cm)
60 80 100 120 14060 80 100 120 140
0.0
0.4
0.8
1.6
1.2
0.0
0.4
0.8
1.6
1.2
r = 0.001
P = 0.996
r = 0.363
P = 0.246
r = 0.544
P = 0.000
r = 0.467
P = 0.053
U
ric
 ac
id
 (m
m
ol
/L
)
U
ric
 ac
id
 (m
m
ol
/L
)
Normal HDL-c and normal TGs (population A)
Low HDL-c and high TGs (population D)
Normal HDL-c and high TGs (population B)
Low HDL-c and normal TGs (population C)
(C1) (C2)
(c)
Figure 5: Correlations between adiponectin andwaist circumference (a), adiponectin and uric acid (b), and uric acid andwaist circumference
(c) in the study populations. (A1) Population A: 𝑟 = −0.363, 𝑃 = 0.004; population D: 𝑟 = −0.093, 𝑃 = 0.688; (A2) population B: 𝑟 = −0.006,
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subfractions: inverse with the large subpopulations and direct
with the small HDL ones, in particular in the subgroup
of patients with normal HDL-c and normal TGs values.
Despite the recognition of an association between low levels
of HDL-c with increased risk for CAD [52, 53], it has been
suggested during the last years that a better indicator of
HDL functionality may be their quality, which depends on
its subpopulation’s type (large versus small) and constituents,
including PON1 activity [54–56]. In our study, HDL quality
is reduced in the two populations with high TGs contents as
well as in the population with normal TGs but low HDL-c
concentration. Thus, both the low HDL-c dyslipidemia and
the hypertriglyceridemia are, per se, even not cumulatively,
promoters of poor HDL quality, viewed by the simultane-
ous reduced content of the large HDL subpopulations and
increased of small ones. This profile was similar to that
found for Ox-LDL concentration, which showed interesting
correlations with the subpopulations, as previously reported.
The implication of TGs levels inHDLquality has been gaining
importance, as reported by other authors [57, 58]. These
studies suggested that particle size of HDL subclasses tend
to be small with increasing TGs concentration, indicating
that HDL maturation might be hampered and efficiency
of reverse cholesterol transport (RCT) might be weakened.
These data suggest that TGs levels were not only signifi-
cantly associated with, but liner with, the contents of HDL
subfractions. Concerning the influence of HDL-c levels on
HDL subpopulations, some studies have demonstrated that
subjects with low HDL-c display marked changes in their
HDL composition and subclass distribution; some of them
indicate that the percentage of larger subfractions as well as
HDLmean particle size is reduced in subjects with lowHDL-
c levels [59, 60], which is in agreement with our results. PON1
activity, which have been indicated as an indicator of HDL
functionality, was unchanged between groups, which is in
agreement with previous data from us in other populations
of cardiovascular risk [25–27], suggesting that HDL subpop-
ulations, rather than PON1 activity, are best markers of HDL
quality. Whether HDL function and/or composition, rather
than total HDL-c content, are better biomarkers of residual
CV risk is an exciting (yet open) issue that deserves additional
efforts from the scientific clinical community.
Inflammation and oxidative stress are key pathways for
endothelial dysfunction and development of atherosclerosis,
being oxidized LDL one of the major players in this
process, together with several mediators of inflammation
[46, 47, 61]. HDL exerts direct endothelial-protective
effects, such as stimulation of endothelial production of
the antiatherogenic molecule nitric oxide, as well as anti-
oxidant, anti-inflammatory and antithrombotic effects
[62–64]. An inflammatory imbalance, as manifested
by increased proinflammatory cytokines, such as the
tumor necrosis factor alpha (TNF-𝛼), increased C-
reactive protein (CRP), and/or reduced levels of anti-
inflammatory and antiatherogenic mediators, such as
adiponectin, has been considered a key factor for the
increased cardiovascular risk in some pathologies [65, 66].
Similar importance is now attributed to the phenomenon
of angiogenesis, which has the vascular endothelial growth
factor (VEGF) as the key biomarker, a peptide growth
factor secreted by vascular endothelial cells that stimulates
vasculogenesis and angiogenesis, which has been involved in
the pathogenesis of cardiovascular diseases, such as
atherosclerosis [67], as well as to the intracellular adhesion
molecules, such as ICAM-1, which has been associated with
the severity of atherosclerosis and cardiovascular events
[68]. Another new marker that deserves our attention is
the uric acid; although uric acid can act as an antioxidant,
excess serum accumulation is often associated with several
conditions and has been suggested as an independent risk
factor for carotid atherosclerosis in patients with CVD, such
as in type 2 diabetes [69]. In our study, although unchanged
values of high sensitivity CRP, TNF-𝛼 and iCAM-1 were
found between the four populations under evaluation, a
reduced concentration of adiponectin and an increased
content of VEGF in the patients’s population with low
HDL-c and high TGs levels were encountered, suggesting
that both conditions contribute to these alterations. Previous
studies have indicated an association of lower adiponectin
levels in populations with increased values of TGs and
reduced values of HDL-c, as well as in healthy individuals
[70, 71]. In our study, adiponectin levels showed important
correlation with HDL subpopulations, inversely with small
HDL subfractions and direct with large ones, but not with
total HDL-c content; in addition, adiponectin levels also
presented inverse correlation with waist circumference. Once
again, those correlations were more evident and strong in the
population with normal HDL-c and normal TGs contents, as
occurred also for the correlations between Ox-LDL andHDL
subpopulations.VEGF serumconcentrationswere previously
correlated with parameters of lipid profile, including TGs, in
hypercholesterolemic patients [72]. Finally, uric acid contents
were significantly increased in both patients’ populations
with high TGs levels, regardless of HDL-c values, suggesting
a direct impact of TGs, as previously reported [73]. Uric
acid levels presented significant inverse correlation with
adiponectin and direct with waist circumference, in
particular in the population with normal HDL-c and normal
TGs contents, in agreement with the previously reported
correlations, between both Ox-LDL and adiponectin and
the large and small HDL subpopulations, suggesting a
strong relationship between these lipidic, oxidative and
inflammatory factor, which might be described yet as
non-traditional markers. The fact that these associations are
less evident in the subgroups of patients with low HDL-c
levels and/or high TGs contents seem to indicate that
under HDL-c dyslipidemia and/or hypertriglyceridemia
there is a deregulation of the factors (lipidic, oxidative, and
inflammatory), with a putative important impact on the
evolution of cardiometabolic vascular disease.
Considering the cardiometabolic impact of low-HDL-c
and/or high TGs levels on this type of patients with previous
cardiovascular risk factors, even when LDL-c concentrations
are adequately managed by antidyslipidemic therapy, ther-
apeutic measures able to improve HDL-c levels and their
quality/functionality and to reduce TGs concentration might
be of key importance to reduce the residual risk previously
identified on this type of populations, namely, by reducing
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the oxidative, inflammatory and angiogenic mechanisms
underlying the evolution of disease. Since the current ther-
apeutic arsenal is of limited impact on HDL-c levels, in
particular the most popular medication, such as statins, and
since a percentage of patients (of concern) present lowHDL-c
dyslipidemia and/or hypertriglyceridemia, nonpharmacolog-
ical measures (including regular physical exercise and low-fat
and low-sugar diets) might deserve more attention, as well
as new and more effective agents that might prove efficacy
to reduce TGs concentration and improve HDL quality and
their beneficial effects, including reduction of Ox-LDL as
well as of deleterious inflammatory mediators. Despite some
disappointing results of some of the recent clinical trials
aimed to access the putative benefits of pharmacotherapy tar-
geting HDL cholesterol, particularly in terms of side-effects
and short and long-term outcome data of cardiovascular
events [74], there are positive results related to the impact
of dalcetrapib, a cholesteryl ester transfer protein (CETP)
inhibitor, on HDL quality [75]. This apparent discrepancy
raises the question as to whether certain biomarkers are
relevant either in specific patient populations or on the
background of therapies, such as statins. More clinical data
of large clinical trials designed to evaluate the impact on
cardiovascular events of drugs directed to modulate HDL
concentration and/or quality are needed to better elucidate
this issue.
5. Conclusions
In a patient population with cardiovascular risk factors, low
HDL-c and/or high TGs levels are associated with a poor
cardiometabolic profile. This condition that often occurs in
patients under lipid-lowering therapy with average LDL-c
concentrations has been called residual cardiovascular risk,
and the patients are those that frequently experience nonfatal
and fatal cardio- and cerebrovascular events. Our study
suggests that this residual cardiovascular risk is better viewed
by nontraditional (emergent) lipid biomarkers, including
HDL subpopulations, oxidized LDL, as well as markers of
inflammation and angiogenesis, such as adiponectin, uric
acid, and VEGF. Proper pharmacological and nonpharma-
cological therapeutic interventions directed to raise HDL-c
levels and functionality and to reduce TGs levels are advisory
preventive measures in this type of CV risk populations.
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